For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.

Date published: April 2010
Dabigatran is a new medicine to prevent blood clots forming after hip or knee replacement surgery. It works by thinning the blood.
Dabigatran is available as capsules that you swallow. It is important that you take dabigatran every day for the prescribed number of days.
Dabigatran appears to be as safe and effective as other blood thinning medicines but, as with these other medicines, you need to be aware of the signs of bleeding.
The active ingredient is the chemical in the medicine that makes the medicine work.
Many medicines are known by their brand names as well as by the name of the active ingredient. Some medicines are available under several different brand names.
The active ingredient of this medicine is dabigatran (pronounced da-BIG-a-tran). It is also known by the brand name Pradaxa.
Dabigatran is used to prevent blood clots forming in the leg veins after hip or knee replacement surgery. The medical term for these blood clots is deep vein thrombosis (DVT).
A blood clot in the legs can travel through the bloodstream to the lungs, where it can block an artery. This is a serious condition known as a pulmonary embolism. It may be life threatening.
People can be prescribed dabigatran through the Pharmaceutical Benefits Scheme (PBS) to prevent blood clots forming after hip or knee replacement surgery.
You may be given another medicine instead to prevent blood clots (see Section 8: Other medicines available).
It is important that you have enough dabigatran capsules to complete your course of treatment.
You will usually be given this medicine 1 to 4 hours after surgery. You will need to continue taking it every day for the prescribed number of days.
Dabigatran must be taken each day at about the same time for:
You may be given enough dabigatran capsules to complete your course of treatment when you leave hospital.
Other hospitals will give you only a small supply of dabigatran capsules and you will need to either:
It is important that you do not accidentally take dabigatran capsules from the hospital and dabigatran capsules you get from your GP or pharmacist at the same time.
Finish the dabigatran capsules from the hospital before you start taking the capsules from your GP or pharmacist.
Make sure you tell your GP or pharmacist the date of your surgery and ask them the date when you should stop taking the capsules.
Write this date on the box and do not take any dabigatran capsules after this date.
Always take dabigatran exactly as prescribed.
The first dose is a single capsule that is usually given 1 to 4 hours after surgery.
After that, the daily dose is two capsules taken together. Each capsule contains 110 milligrams of medicine, so the total dose is 220 milligrams.
If you have kidney problems, or are taking other medicines that thin your blood, your doctor will prescribe a lower dose of 150 milligrams (two capsules of 75 milligrams).
You should take your daily dose at about the same time each day. Swallow the two capsules with water. They can be taken with or without food.
If you forget to take a dabigatran capsule, do not take a double dose the next day because this will increase the risk of bleeding.
For a list of possible side effects, see the consumer medicine information (CMI) leaflet for dabigatran.
Ask your doctor about the possible side effects of this medicine before you use it.
Always tell your doctor about any changes to your condition if you are taking a new medicine.
You can also discuss side effects with a pharmacist, by calling the Adverse Medicines Event (AME) Line on 1300 134 237 (Mon–Fri, 9am–5pm).
All medicines can have side effects. Sometimes the side effects are serious, but most of the time they are not.
For dabigatran and other blood thinning medicines, the main risk is bleeding.
You may find that some blood seeps through the dressing after your operation. Some seepage is normal, but if you think that the bleeding is excessive speak to your doctor about it.
You should seek urgent medical attention if you have:
Internal bleeding is harder to detect, but can be very serious. If you experience any of the following, contact your doctor immediately or go to the emergency department at your nearest hospital:
If you experience any serious injury, you are at greater risk of internal bleeding. You must get immediate medical attention, particularly if you hit your head.
A clinical trial is a research study conducted with patients, which compares one treatment with one or more other treatments, to assess its effectiveness and safety.
Dabigatran has been tested in clinical trials, but it is a new medicine so the full range of side effects is not known. You should be aware of this and see your doctor straight away if you have any concerns.
If you stop taking dabigatran too early you are at greater risk of developing a blood clot in the veins of your leg. Make sure that you take it for the number of days that your doctor, pharmacist or nurse has told you.
While you are taking dabigatran, you should talk to your doctor before taking other medicines that can increase your risk of bleeding. These include:
If you have a mild headache or other pain, or fever associated with a cold, you may use paracetamol (Panadol, Panamax).
Your hospital doctor will consider any other health problems you might have before prescribing dabigatran for you.
Dabigatran may not be suitable for you if you have:
Some other medicines can interact with dabigatran. You should talk to your doctor before taking any other medicine from a pharmacy, supermarket or health food store.
Remember that risks and benefits differ between medicines and from person to person.
Some medicines to prevent blood clots after hip or knee replacement surgery are given as a daily injection. They include dalteparin (Fragmin), enoxaparin (Clexane) and fondaparinux (Arixtra).
Dabigatran is a new blood thinning (anticoagulant) medicine that is available in capsule form. Another new anticoagulant — called rivaroxaban (Xarelto) — is available in tablet form. These two medicines work in slightly different ways, but in clinical trials both were found to be about as effective as a daily injection of enoxaparin. The risk of bleeding was also similar.
Most medicines prescribed by your doctor are covered by the PBS. This means that the Australian Government pays part of the cost of your medicine.
You will need to pay the full price if the medicine is not available on the PBS, or is not available on the PBS for your specific condition.
For more information see pbs.gov.au.
The full cost of dabigatran to the Australian Government varies depending on the strength of the capsules and the size of the pack.
The costs are as follows:
If you get dabigatran through the Pharmaceutical Benefits Scheme (PBS), the Australian Government pays most of the cost and you will pay only a part, called the co-payment.
At the time of publication, the co-payment for people who are entitled to get dabigatran through the PBS was:
If you are not eligible to get dabigatran through the PBS, you will need to pay the full price for a prescription.
In addition to taking an anticoagulant medicine such as dabigatran, you should wear compression stockings while you are recovering from hip or knee replacement surgery. These further reduce your risk of blood clots.
You will also be given a program of exercises to help with your recovery.
Read the consumer medicine information (CMI) leaflet for this medicine. The CMI will tell you:
You can get the CMI leaflet for Pradaxa (dabigatran) from:
Call the Adverse Medicine Events (AME) Line on 1300 134 237 (Mon–Fri, 9am–5pm EST).
The AME Line lets you report and discuss side effects that might be related to your medicine. The side effects of your medicine — but not your personal details — are reported to the Australian medicines regulatory agency (the Therapeutic Goods Administration or TGA for short). The information helps to improve the safe use of medicines.
See AME Line for more information.
See About Medicine Update for more information about this publication.
NPS acknowledges the contribution of Arthritis Australia in the production of this article.
Date published: 2010-04-12 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.